Albumin binding improves nanobody pharmacokinetics for dual-modality PET/NIRF imaging of CEACAM5 in colorectal cancer models

This publication has 35 references indexed in Scilit:

• Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment
  Trends in Pharmacological Sciences, 2016
• Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life
  mAbs, 2016
• Half-life extended biotherapeutics
  Expert Opinion on Biological Therapy, 2016
• Nanobody-functionalized PEG-b-PCL polymersomes and their targeting study
  Journal of Biotechnology, 2015
• Nanobody: The “Magic Bullet” for Molecular Imaging?
  Theranostics, 2014
• THE ALBUMIN-BINDING DOMAIN AS A SCAFFOLD FOR PROTEIN ENGINEERING
  Computational and Structural Biotechnology Journal, 2013
• Antibody therapy of cancer
  Nature Reviews Cancer, 2012
• Strategies for extended serum half-life of protein therapeutics
  Current Opinion in Biotechnology, 2011
• Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
  The Journal of Immunology, 2010
• General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold
  Journal of Biological Chemistry, 2009